Seeking Alpha

Sarepta Therapeutics (SRPT) says the FDA is considering accelerated approval of eteplirsen for...

Sarepta Therapeutics (SRPT) says the FDA is considering accelerated approval of eteplirsen for the treatment of Duchenne muscular dystrophy. The agency has requested SRPT provide additional information from its existing dataset to help facilitate a decision on its acceptability for a New Drug Application filing under the Subpart H Accelerated Approval regulatory pathway. Shares -0.4% AH.
From other sites
Comments (1)
  • rrobster
    , contributor
    Comments (161) | Send Message
     
    Shares were -6.52% AH. Not everyone saw this as good news but they should have.
    15 Apr 2013, 11:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs